Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
AIDS Research and Human Retroviruses|March 1, 1996
Autoantibodies to CD4 in HIV type 1-exposed seronegative individualsS E Burastero, D Gaffi, L Lopalco, et al.
Antiviral Therapy|August 1, 1996
A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infectionS Vella, A Lazzarin, G Carosi, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 19, 2015
Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trialM Ripa, M Pogliaghi, S Chiappetta, et al.
HIV Medicine|September 4, 2010
Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT)S L Pett, C Carey, E Lin, et al.
The Journal of Infectious Diseases|April 25, 2001
Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapyG Tambussi, S Ghezzi, S Nozza, et al.
The Journal of Experimental Medicine|August 4, 1997
Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 alleleL Furci, G Scarlatti, S Burastero, et al.
Journal of Biological Regulators and Homeostatic Agents|May 11, 2002
Implementation of an Italian multicentric care network for early HIV infection diagnosis: 1999-2001 reportB Capiluppi, A Saracco, N Gianotti, et al.
Journal of Biological Regulators and Homeostatic Agents|April 14, 2000
Four drug-HAART in primary HIV-1 infection: clinical benefits and virologic parametersB Capiluppi, D Ciuffreda, G P Quinzan, et al.
The Journal of Clinical Investigation|March 23, 2000
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNAG P Rizzardi, R J De Boer, S Hoover, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 7, 1997
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremiaG Pantaleo, J F Demarest, T Schacker, et al.
Pageof 8